KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to $2.5 million.

  • AbCellera Biologics' Gains from Investment Securities fell 90.22% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.3 million, marking a year-over-year decrease of 123.61%. This contributed to the annual value of $19.7 million for FY2024, which is 43.96% up from last year.
  • As of Q3 2025, AbCellera Biologics' Gains from Investment Securities stood at $2.5 million, which was down 3.96% from $2.6 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Gains from Investment Securities high stood at $25.1 million for Q3 2024, and its period low was -$16.2 million during Q4 2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was $3.5 million (2023), whereas its average is $3.7 million.
  • In the last 5 years, AbCellera Biologics' Gains from Investment Securities soared by 43,453.57% in 2021 and then plummeted by 565.45% in 2024.
  • AbCellera Biologics' Gains from Investment Securities (Quarterly) stood at $3.2 million in 2021, then skyrocketed by 83.62% to $5.9 million in 2022, then plummeted by 41.17% to $3.5 million in 2023, then tumbled by 565.45% to -$16.2 million in 2024, then tumbled by 90.22% to $2.5 million in 2025.
  • Its Gains from Investment Securities was $2.5 million in Q3 2025, compared to $2.6 million in Q2 2025 and $1.9 million in Q1 2025.